[PDF][PDF] CTLA4Ig: bridging the basic immunology with clinical application
JA Bluestone, EWS Clair, LA Turka - Immunity, 2006 - cell.com
JA Bluestone, EWS Clair, LA Turka
Immunity, 2006•cell.comAfter a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the
treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28
costimulation. In this perspective, we discuss the science that led to CTLA4Ig development
and the clinical challenges in bringing the drug from the bench to the bedside.
treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28
costimulation. In this perspective, we discuss the science that led to CTLA4Ig development
and the clinical challenges in bringing the drug from the bench to the bedside.
After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.
cell.com